Related Experiment Video
Updated: Dec 9, 2025
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.8K
Pulmonary sarcomatoid carcinoma: progress, treatment and expectations
Xin Li1, Di Wu1, Hongyu Liu2
1Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Therapeutic Advances in Medical Oncology
|September 14, 2020
Summary
Pulmonary sarcomatoid carcinoma (PSC) is a rare, aggressive lung cancer with poor outcomes. Novel targeted and immune therapies show promise for improving treatment and patient prognosis.
Area of Science:
- Oncology
- Pulmonary Medicine
- Molecular Biology
Background:
- Pulmonary sarcomatoid carcinoma (PSC) is a rare (0.1-0.4% of lung tumors), highly invasive malignancy.
- PSC exhibits aggressive behavior, frequent metastasis, and poor response to conventional treatments like chemotherapy and radiotherapy.
Purpose of the Study:
- To review the clinicopathologic features, molecular characteristics, and traditional treatments for PSC.
- To explore the latest advancements in targeted therapies and immunotherapies for managing PSC.
Main Methods:
- Literature review of clinical and molecular data on PSC.
- Analysis of recent research on novel therapeutic strategies, including gene sequencing and immunotherapy.
Main Results:
- Traditional treatments show limited efficacy due to PSC's aggressive nature.
- Targeted therapies (e.g., EGFR/VEGFR2, ALK inhibitors) and immunotherapies (e.g., PD-1/PD-L1) represent promising new treatment avenues.
Conclusions:
- Novel targeted and immune-based therapies offer potential for improved management of pulmonary sarcomatoid carcinoma.
- Ongoing clinical trials are expected to provide further insights into effective treatment options for PSC patients.
Related Concept Videos
02:07Tumor Progression
7.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
02:57Targeted Cancer Therapies
8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.5K
01:21Cancer Survival Analysis
560
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
560
01:28Pulmonary Tuberculosis V
375
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
375
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
313
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
313